996 related articles for article (PubMed ID: 33887358)
1. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
[TBL] [Abstract][Full Text] [Related]
2. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
[TBL] [Abstract][Full Text] [Related]
3. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
4. Dihydrosphingolipids are associated with steatosis and increased fibrosis damage in non-alcoholic fatty liver disease.
Babiy B; Ramos-Molina B; Ocaña L; Sacristán S; Burgos-Santamaría D; Martínez-Botas J; Busto R; Perna C; Frutos MD; Albillos A; Pastor Ó
Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Jul; 1868(7):159318. PubMed ID: 37059386
[TBL] [Abstract][Full Text] [Related]
5. A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy.
Ramos-Molina B; Castellano-Castillo D; Pastor O; Ocaña-Wilhelmi L; Fernández-García D; Romero-Gómez M; Cardona F; Tinahones FJ
Obes Surg; 2019 Mar; 29(3):983-989. PubMed ID: 30488259
[TBL] [Abstract][Full Text] [Related]
6. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease.
Jung Y; Lee MK; Puri P; Koo BK; Joo SK; Jang SY; Lee DH; Jung YJ; Kim BG; Lee KL; Park TS; Kang KT; Ryu DH; Kang SW; Kim D; Oh S; Kim W; Hwang GS
Aliment Pharmacol Ther; 2020 Nov; 52(10):1603-1614. PubMed ID: 32892365
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease stratification by liver lipidomics.
Vvedenskaya O; Rose TD; Knittelfelder O; Palladini A; Wodke JAH; Schuhmann K; Ackerman JM; Wang Y; Has C; Brosch M; Thangapandi VR; Buch S; Züllig T; Hartler J; Köfeler HC; Röcken C; Coskun Ü; Klipp E; von Schoenfels W; Gross J; Schafmayer C; Hampe J; Pauling JK; Shevchenko A
J Lipid Res; 2021; 62():100104. PubMed ID: 34384788
[TBL] [Abstract][Full Text] [Related]
8. Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis.
Zhu Q; Li H; Ao Z; Xu H; Luo J; Kaurich C; Yang R; Zhu PW; Chen SD; Wang XD; Tang LJ; Li G; Huang OY; Zheng MH; Li HP; Liu F
J Nanobiotechnology; 2022 Jul; 20(1):349. PubMed ID: 35897102
[TBL] [Abstract][Full Text] [Related]
9. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity.
Jorge ASB; Andrade JMO; Paraíso AF; Jorge GCB; Silveira CM; de Souza LR; Santos EP; Guimaraes ALS; Santos SHS; De-Paula AMB
Obes Res Clin Pract; 2018; 12(Suppl 2):1-8. PubMed ID: 27083404
[TBL] [Abstract][Full Text] [Related]
10. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
[TBL] [Abstract][Full Text] [Related]
11. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
[TBL] [Abstract][Full Text] [Related]
12. Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis.
Guerra S; Mocciaro G; Gastaldelli A
Eur J Clin Invest; 2022 Mar; 52(3):e13695. PubMed ID: 34695228
[TBL] [Abstract][Full Text] [Related]
13. Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B.
Yang RX; Hu CX; Sun WL; Pan Q; Shen F; Yang Z; Su Q; Xu GW; Fan JG
Sci Rep; 2017 Sep; 7(1):10517. PubMed ID: 28874844
[TBL] [Abstract][Full Text] [Related]
14. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS
Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876
[TBL] [Abstract][Full Text] [Related]
16. Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study.
Ooi GJ; Burton PR; Bayliss J; Raajendiran A; Earnest A; Laurie C; Kemp WW; McLean CA; Roberts SK; Watt MJ; Brown WA
Obes Surg; 2019 Jan; 29(1):99-108. PubMed ID: 30229460
[TBL] [Abstract][Full Text] [Related]
17. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
[TBL] [Abstract][Full Text] [Related]
18. Lipidomics in non-alcoholic fatty liver disease.
Kartsoli S; Kostara CE; Tsimihodimos V; Bairaktari ET; Christodoulou DK
World J Hepatol; 2020 Aug; 12(8):436-450. PubMed ID: 32952872
[TBL] [Abstract][Full Text] [Related]
19. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
20. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity.
Anjani K; Lhomme M; Sokolovska N; Poitou C; Aron-Wisnewsky J; Bouillot JL; Lesnik P; Bedossa P; Kontush A; Clement K; Dugail I; Tordjman J
J Hepatol; 2015 Apr; 62(4):905-12. PubMed ID: 25450212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
